Arcus Biosciences Inc
NYSE:RCUS

Watchlist Manager
Arcus Biosciences Inc Logo
Arcus Biosciences Inc
NYSE:RCUS
Watchlist
Price: 8.93 USD -6.1% Market Closed
Market Cap: 945.6m USD

Relative Value

The Relative Value of one RCUS stock under the Base Case scenario is 11.46 USD. Compared to the current market price of 8.93 USD, Arcus Biosciences Inc is Undervalued by 22%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RCUS Relative Value
Base Case
11.46 USD
Undervaluation 22%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
58
vs Industry
67
Median 3Y
6
Median 5Y
11.2
Industry
6.9
Forward
7.7
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-5.3
Industry
23
Forward
-2.1
vs History
vs Industry
14
Median 3Y
-4.3
Median 5Y
-4.3
Industry
19.7
vs History
vs Industry
10
Median 3Y
-4.2
Median 5Y
-4.2
Industry
22.8
vs History
93
vs Industry
41
Median 3Y
2.5
Median 5Y
2.6
Industry
2.6
vs History
31
vs Industry
81
Median 3Y
2.8
Median 5Y
4.5
Industry
7.4
Forward
8.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.3
vs History
vs Industry
Median 3Y
-1.4
Median 5Y
-1.8
Industry
4.1
Forward
-2.1
vs History
vs Industry
Median 3Y
-1.3
Median 5Y
-1.8
Industry
4.1
Forward
-2.1
vs History
vs Industry
18
Median 3Y
-1.7
Median 5Y
-1.7
Industry
4.9
vs History
vs Industry
14
Median 3Y
-1.6
Median 5Y
-1.6
Industry
3.6
vs History
90
vs Industry
68
Median 3Y
2
Median 5Y
2.4
Industry
4.7

Multiples Across Competitors

RCUS Competitors Multiples
Arcus Biosciences Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Arcus Biosciences Inc
NYSE:RCUS
946.6m USD 6.7 -2.4 -2.3 -2.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 873 287.2 -165 747.6 -201 270.4 -198 973.7
US
Abbvie Inc
NYSE:ABBV
328.7B USD 5.7 79.1 15.1 22.3
US
Amgen Inc
NASDAQ:AMGN
154.7B USD 4.5 26.1 14.1 23.2
US
Gilead Sciences Inc
NASDAQ:GILD
137B USD 4.8 23 10 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.6B USD 10.2 -114.9 24.4 25.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 020.1 -515.5 -561.3 -546.4
AU
CSL Ltd
ASX:CSL
119.6B AUD 5.1 28 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
53B USD 3.8 11.8 10.4 11.7
US
Seagen Inc
F:SGT
39.3B EUR 19.5 -59.7 -64.3 -58
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
39.2B USD 16.9 -147.2 -650.8 -326.1
P/S Multiple
Revenue Growth P/S to Growth
US
Arcus Biosciences Inc
NYSE:RCUS
Average P/S: 3 170 489.5
6.7
-2%
N/A
FR
Pharnext SCA
OTC:PNEXF
34 873 287.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
2 020.1
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
3.8
5%
0.8
US
S
Seagen Inc
F:SGT
19.5
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.9
29%
0.6
P/E Multiple
Earnings Growth PEG
US
Arcus Biosciences Inc
NYSE:RCUS
Average P/E: 33.6
Negative Multiple: -2.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 747.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
79.1
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -114.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515.5 N/A N/A
AU
CSL Ltd
ASX:CSL
28
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
7%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -147.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Arcus Biosciences Inc
NYSE:RCUS
Average EV/EBITDA: 15.2
Negative Multiple: -2.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 270.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.1
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.1
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.3 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.4
11%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -650.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Arcus Biosciences Inc
NYSE:RCUS
Average EV/EBIT: 19.7
Negative Multiple: -2.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 973.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.2
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -546.4 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.7
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -326.1 N/A N/A